摘要: Le recepteur du facteur de croissance epidermique (EGFR) est une glycoproteine transmembranaire 170 kDA, membre la famille des recepteurs ErbB (ou HER) a activite tyrosine kinase. La structure ľEGFR comporte trois domaines distincts: un domaine extra-cellulaire (621 acides amines), site fixation ligand, hydrophobe (23 amines) permettant ľancrage dans membrane plasmique, et intracellulaire kinase (542 amines). Ľactivite necessite ďun phosphore sur sites majeurs ďautophosphorylation.
springer.com
sci-hub.st 参考文章(23)
Marce Peeters, Salvatore Siena, Eric van Cutsem, The best manuscript: Open-label phase 3 trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer[含 解説者コメント] メディカルオンコロジスト. ,vol. 3, pp. 28- 30 ,(2007)
A. de Gramont, Emmanuel Van Cutsem, J. Sastre, A. Cervantes, J. Van Laethem, Yves Humblet, E. Casac, A. Zubel, N. Gascon, Thibaut André, Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study Ejc Supplements. ,vol. 3, pp. 181- 182 ,(2005)
U Graeven, B Kremer, Th Südhoff, B Killing, F Rojo, D Weber, J Tillner, C Ünal, W Schmiegel, Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer British Journal of Cancer. ,vol. 94, pp. 1293- 1299 ,(2006) , 10.1038/SJ.BJC.6603083
Udo Vanhoefer, Mitra Tewes, Federico Rojo, Olaf Dirsch, Norbert Schleucher, Oliver Rosen, Joachim Tillner, Andreas Kovar, Ada H. Braun, Tanja Trarbach, Siegfried Seeber, Andreas Harstrick, José Baselga, Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor Journal of Clinical Oncology. ,vol. 22, pp. 175- 184 ,(2004) , 10.1200/JCO.2004.05.114
Nasser Hanna, Rogerio Lilenbaum, Rafat Ansari, Thomas Lynch, Ramaswamy Govindan, Pasi A. Jänne, Philip Bonomi, Phase II Trial of Cetuximab in Patients With Previously Treated Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 24, pp. 5253- 5258 ,(2006) , 10.1200/JCO.2006.08.2263
José Baselga, José M. Trigo, Jean Bourhis, Jacques Tortochaux, Hernán Cortés-Funes, Ricardo Hitt, Pere Gascón, Nadia Amellal, Andreas Harstrick, André Eckardt, Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck Journal of Clinical Oncology. ,vol. 23, pp. 5568- 5577 ,(2005) , 10.1200/JCO.2005.07.119
Christiane D. Thienelt, Paul A. Bunn, Nasser Hanna, Arthur Rosenberg, Michael N. Needle, Michael E. Long, Daniel L. Gustafson, Karen Kelly, Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer Journal of Clinical Oncology. ,vol. 23, pp. 8786- 8793 ,(2005) , 10.1200/JCO.2005.03.1997
C. Kollmannsberger, M. Schittenhelm, F. Honecker, J. Tillner, D. Weber, K. Oechsle, L. Kanz, C. Bokemeyer, A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC) Annals of Oncology. ,vol. 17, pp. 1007- 1013 ,(2006) , 10.1093/ANNONC/MDL042
G. Folprecht, M.P. Lutz, P. Schöffski, T. Seufferlein, A. Nolting, P. Pollert, C.-H. Köhne, Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma Annals of Oncology. ,vol. 17, pp. 450- 456 ,(2006) , 10.1093/ANNONC/MDJ084
David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype, Ian Chau, Eric Van Cutsem, None, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 337- 345 ,(2004) , 10.1056/NEJMOA033025